119 related articles for article (PubMed ID: 7033951)
21. Cardiovascular protective properties of indapamide.
Campbell DB; Brackman F
Am J Cardiol; 1990 May; 65(17):11H-27H. PubMed ID: 2184650
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy and safety of indapamide 1.5 mg sustained release coated tablets in the therapy of arterial hypertension].
Asmar R
Ann Cardiol Angeiol (Paris); 1998 Feb; 47(2):94-104. PubMed ID: 9772936
[TBL] [Abstract][Full Text] [Related]
23. Indapamide: a unique diuretic?
Conner CS
Drug Intell Clin Pharm; 1983 Dec; 17(12):898-9. PubMed ID: 6653405
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of indapamide 1.5 mg, sustained release, in the lowering of systolic blood pressure.
London GM
J Hum Hypertens; 2004 Dec; 18 Suppl 2():S9-S14. PubMed ID: 15592572
[TBL] [Abstract][Full Text] [Related]
25. [Structural and functional changes of the microcirculation in hypertension: influence of pharmacological therapy].
Agabiti-Rosei E
Drugs; 2003; 63 Spec No 1():19-29. PubMed ID: 12708883
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular effects of indapamide on frog hearts and open-chest cats.
Hemwall EL; Dipalma JR
Arch Int Pharmacodyn Ther; 1980 Dec; 248(2):225-37. PubMed ID: 6971631
[TBL] [Abstract][Full Text] [Related]
27. The possible mode of action of indapamide: a review.
Campbell DB
Curr Med Res Opin; 1983; 8 Suppl 3():9-24. PubMed ID: 6352188
[TBL] [Abstract][Full Text] [Related]
28. Alteration of renal receptors for atrial natriuretic peptide and vasopressin in spontaneously hypertensive rats treated with antihypertensive diuretics.
Ogura T; Nishida N; Watanabe H; Omiya T; Yamauchi T; Hosoya M; Hirata H; Kashihara N; Ota Z
Res Commun Chem Pathol Pharmacol; 1994 Feb; 83(2):165-78. PubMed ID: 8202630
[TBL] [Abstract][Full Text] [Related]
29. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
30. Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.
Gosse P
Expert Rev Cardiovasc Ther; 2006 May; 4(3):319-33. PubMed ID: 16716093
[TBL] [Abstract][Full Text] [Related]
31. Combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide activate postnatal vasculogenesis in spontaneously hypertensive rats.
You D; Cochain C; Loinard C; Vilar J; Mees B; Duriez M; Lévy BI; Silvestre JS
J Pharmacol Exp Ther; 2008 Jun; 325(3):766-73. PubMed ID: 18309090
[TBL] [Abstract][Full Text] [Related]
32. Non-invasive cardiovascular assessment of indapamide in patients with essential hypertension.
Dunn FG; Hillis WS; Tweddel A; Rae AP; Lorimer AR
Postgrad Med J; 1981; 57 Suppl 2():19-22. PubMed ID: 7322955
[TBL] [Abstract][Full Text] [Related]
33. Lack of effect of bilateral nephrectomy on the pharmacokinetics of 14C-indapamide (REV 2555) and its metabolites in the dog.
Klunk LJ; Mangat S; Treitman JA; Grebow PE
Res Commun Chem Pathol Pharmacol; 1983 Nov; 42(2):223-34. PubMed ID: 6658187
[TBL] [Abstract][Full Text] [Related]
34. Regulation of coronary blood flow during exercise.
Duncker DJ; Bache RJ
Physiol Rev; 2008 Jul; 88(3):1009-86. PubMed ID: 18626066
[TBL] [Abstract][Full Text] [Related]
35. Serum lipoprotein levels during long-term treatment of hypertension with indapamide.
Meyer-Sabellek W; Gotzen R; Heitz J; Arntz HR; Schulte KL
Hypertension; 1985; 7(6 Pt 2):II170-4. PubMed ID: 4077236
[TBL] [Abstract][Full Text] [Related]
36. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies.
Weidmann P
Drug Saf; 2001; 24(15):1155-65. PubMed ID: 11772148
[TBL] [Abstract][Full Text] [Related]
37. Blood sugar regulation during treatment with indapamide in hypertensive diabetics.
Roux P; Courtois H
Postgrad Med J; 1981; 57 Suppl 2():70-2. PubMed ID: 7322961
[TBL] [Abstract][Full Text] [Related]
38. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
Prichard BN; Owens CW; Graham BR
J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
[TBL] [Abstract][Full Text] [Related]
39. A review of 10 years of experience with indapamide as an antihypertensive agent.
Thomas JR
Hypertension; 1985; 7(6 Pt 2):II152-6. PubMed ID: 4077233
[TBL] [Abstract][Full Text] [Related]
40. Effect of indapamide on urinary calcium excretion in patients with and without urinary stone disease.
Ceylan K; Topal C; Erkoc R; Sayarlioglu H; Can S; Yilmaz Y; Dogan E; Algun E; Gonulalan H
Ann Pharmacother; 2005 Jun; 39(6):1034-8. PubMed ID: 15840731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
